Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co‐formulation therapy twice‐daily with free combination of GLP‐1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Practice"
DOI: 10.1111/ijcp.13734
Abstract: We compared the efficacy and safety of insulin degludec/insulin aspart co‐formulation (IDegAsp) twice‐daily to a free combination of basal insulin degludec and GLP‐1 receptor agonist liraglutide (IDeg + Lira) once‐daily for patients with inadequately controlled… read more here.
Keywords: insulin; daily free; twice daily; insulin aspart ... See more keywords